• Hasan Karanlik, Sidika Kurul, Pinar Saip, Ersin Selcuk Unal, Fatma Sen, Rian Disci, and Erkan Topuz.
• Department of Surgery, Istanbul University, Institute of Oncology, Capa, Turkey. hasankaranlik@yahoo.com
• Am. J. Surg. 2011 Jul 1;202(1):10-5.

BackgroundThis study evaluated whether prophylactic treatment with a cefazolin could prevent infections in patients who had a surgically inserted totally implantable venous access device (TIVAD).MethodsWe conducted a prospective, randomized, double-blind, placebo-controlled trial comparing wound infection rates in 404 patients (203 received prophylactic cefazolin, 201 received a placebo) undergoing TIVAD insertion. Infections were evaluated 3, 7, 14, and 30 days after discharge and outcomes were compared and analyzed.ResultsGroups were well matched for all preoperative variables studied, including comorbid conditions. Superficial surgical site infection developed in 5 patients (2.5%) from the antibiotic group and 6 (3%) from the placebo group (P = .75). One from each group developed deep surgical site infection. Both patients were readmitted and underwent repeated debridement, which eventually resulted in port loss in 1 patient.ConclusionsWe do not recommend the use of prophylactic antibiotics in TIVAD insertion because they will not decrease the already low rate of postoperative infectious complications. Registration number NCT00867295 (http://www.clinicaltrials.gov).Copyright © 2011 Elsevier Inc. All rights reserved.

22 keywords...

hide…